Loading
(taurolidine and heparin) catheter lock solution / Central Line Associated Blood Stream Infections (CLABSI) / Heparin · Phase 3 Trial
ClinicalTrials.gov · August 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized controlled trial registration comparing taurolidine-heparin catheter lock solution (DEFENCATH®) to heparin alone for prevention of CLABSI in adults receiving home TPN via central venous catheter. The study is currently recruiting and no efficacy or safety results have been posted in this registry record.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Prevention purpose. Central Line Associated Blood Stream Infections (CLABSI); age from 18 Years. Intervention: DefenCath®. Compared with: Control — Active Comparator. n = 200. 22 sites: United States, Turkey (Türkiye).
This is a Phase 3 randomized controlled trial registration comparing taurolidine-heparin catheter lock solution (DEFENCATH®) to heparin alone for prevention of CLABSI in adults receiving home TPN via central venous catheter. The study is currently recruiting and no efficacy or safety results have been posted in this registry record.
This registry record contains no efficacy or safety results; outcomes are not yet reported
The source did not state who this applies to in practice.
This is a Phase 3 RCT registration with no reported results; the study is actively recruiting and outcomes have not yet been published in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06822426). This is a study registration, not published results. Lead sponsor: CorMedix Therapeutics. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Central Line Associated Blood Stream Infections (CLABSI). Interventions: DRUG: (taurolidine and heparin) catheter lock solution; DRUG: Heparin. Primary outcome measures: Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study , Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months). Brief summary: This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.